Central Alerting System
View Alert

Originator: CMO Messaging

From: CMO Messaging

Issue date: Originally issued on 31-Jan-2022 09:43:11. This version was issued on 31-Jan-2022 09:43:13

This alert has been issued to:
  • MHRA (Medicines) Drug Alerts (Various Recipients)
  • Other contacts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • NHS Foundation Trusts (England) - Medical Director
  • NHS Foundation Trusts (England) - Chief Executive
  • Special Health Authorities
  • NHS Trusts (England) - Medical Director
  • CMO Urgent Messages - Non-NHS Recipients on Public Health Link
  • MHRA (Medicines) Drug Alerts - Non-NHS Recipients
  • Territorial CMOs in Northern Ireland, Scotland & Wales
  • Regional Directors of Public Health
  • Consultants in Communicable Diseases
  • CMO Urgent Messages - Recipients on Public Health Link
  • Director of Public Health
  • NHS Trusts (England) - Chief Executive
  • Out of hours contacts

Action category: Action

Title: Interleukin-6 inhibitors (tocilizumab or sarilumab) for adult patients hospitalised due to COVID-19

Broadcast content:
***05/05/2022 - An updated Clinical guide has been attached following publication.***

***24 February 2022: The ‘Clinical Guide - Therapies for Patients Hospitalised Due to COVID-19’ published on 24 February 2022 has been added to this page. ***

***31 January 2022: The interim Clinical Commissioning Policy has been updated: Correction to wording in exclusion criteria and cautions section of policy***

The published policy has been updated to reflect that the IL-6 inhibitor tocilizumab (RoActemra) is now licensed in the treatment of adult patients hospitalised due to COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation (please note that additional exclusion criteria now apply).  Sarilumab (Kevzara), an off-label treatment, should continue to be considered where tocilizumab is not available or cannot be used.

Additional information: This alert is not relevant to Primary Care.

Alert reference: CEM/CMO/2022/004


Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency